MediPharm Labs Achieves 14% Revenue Growth in Q2 2025

MediPharm Labs ( (TSE:LABS) ) has issued an update.

MediPharm Labs reported a 14% increase in Q2 2025 revenue, reaching $11.8 million, driven by a 50% growth in international medical cannabis sales, which now account for 57% of total revenue. Despite the financial impact of a proxy contest, the company maintained a strong cash balance and continues to focus on revenue growth and cost management to enhance profitability, demonstrating resilience in its commercial strategy.

Spark’s Take on TSE:LABS Stock

According to Spark, TipRanks’ AI Analyst, TSE:LABS is a Neutral.

MediPharm Labs’ overall score reflects a mix of improving financial metrics and strategic growth opportunities, offset by significant profitability challenges and valuation concerns. The earnings call provided optimism with record margins and international growth, but technical indicators and valuation metrics suggest caution.

To see Spark’s full report on TSE:LABS stock, click here.

More about MediPharm Labs

MediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids, focusing on international medical cannabis markets.

Average Trading Volume: 235,222

Technical Sentiment Signal: Hold

Current Market Cap: C$31.56M

See more insights into LABS stock on TipRanks’ Stock Analysis page.